Cayman Integrin α5β1 Chimeric Monoclonal Antibody (Clone M200 (Volociximab))

Integrin α5β1 is a cell adhesion receptor that is involved in the attachment of cells to the extracellular matrix (ECM) and cell-cell interactions.¹ It is composed of a heterodimer of two integrin subunits, integrin α5, also known as CD49E, that binds to the RGD sequence and central cell-binding domain of fibronectin, and integrin β1, also known as CD29, that interacts with the cytoskeleton and intracellular signaling molecules.^2,3 Integrin α5β1 localizes to the cell surface and mediates outside-in and inside-out signaling cascades that regulate angiogenesis and cell differentiation, as well as migration, development, and hematopoiesis.^4,1 An anti-integrin α5β1 monoclonal antibody inhibits tube formation and proliferation of human umbilical vein endothelial cells (HUVECs) in vitro and prevents laser-induced choroidal neovascularization in a cynomolgus monkey model of macular degeneration.⁵ Integrin α5β1 levels are increased in tumoral neovasculature.⁶ Caymans Integrin α5β1 Chimeric Monoclonal Antibody (Clone M200 (Volociximab)) was produced recombinantly from the original M200 antibody sequence and can be used for ELISA, flow cytometry (FC), immunofluorescence (IF), and immunohistochemistry (IHC) applications. The M200 antibody was generated by fusing human IgG4κ constant domains to the antigen-binding domain of a mouse anti-integrin α5β1 monoclonal antibody.⁵

WARNING This product is not for human or veterinary use.